AI Meets Maternity: MediKarma Acquires Nanell for Proactive Pregnancy Care

SAN RAMON, CA – February 23, 2026 – In a significant move set to reshape digital maternal health, AI-driven healthcare platform MediKarma has announced its acquisition of Nanell, a specialized digital solution for the pregnancy journey, from the Japanese global manufacturer Niterra Co., Ltd. The deal integrates Nanell’s intellectual property, assets, and operations into MediKarma’s platform, fast-tracking the company’s expansion into women’s health and reinforcing its commitment to proactive, value-based care.

A New Era for Digital Maternal Health

The acquisition signals a strategic push to address the critical gaps in traditional maternity care—specifically, the moments that occur between scheduled doctor's visits. Nanell, created by Niterra's venture arm, provides expectant mothers with expert consultation, guided resources, and health tracking. It has garnered attention for strong early results, including high user retention and targeted support for both first-time and high-risk pregnancies.

By absorbing Nanell, MediKarma aims to weave this specialized expertise directly into its comprehensive health data platform. The goal is to move beyond simple tracking and offer a deeply integrated experience where patient-reported data from the Nanell solution informs clinical workflows in real time.

“This acquisition immediately fast-tracks MediKarma’s expansion into women’s health with a solution purpose-built for the critical moments that happen between visits,” said Kris Narayan, CEO of MediKarma, in a statement. “By integrating Nanell’s proven pregnancy expertise, we empower our members with clearer, real-time guidance and route meaningful signals back to care teams.”

The integration process includes a 60–90 day knowledge transfer, with Niterra Ventures providing transitional support to ensure a seamless handover.

The AI Advantage in a Crowded Market

The digital women's health market, often called "Femtech," is a dynamic and increasingly competitive space. Projections show the industry growing exponentially, with some estimates suggesting it could cross $246 billion by 2035. This boom has produced a plethora of apps and services, from fertility trackers to postpartum support networks. Key players like Maven Clinic and Wildflower Health have already established significant footprints by offering virtual care and digital solutions.

MediKarma's strategy is not to simply add another app to the market, but to create a unified system. Its core platform is designed to synthesize disparate data sources—including electronic medical records (EMR), insurance claims, pharmacy data, and inputs from wearable devices—into a single, longitudinal patient profile.

The addition of Nanell provides a rich, new layer of highly specific, patient-reported data focused on the maternity journey. MediKarma's AI can analyze this data to identify subtle but significant changes in a patient's condition, flagging potential risks like preeclampsia or gestational diabetes far earlier than a standard check-up schedule might allow. This fulfills the company's B2B2C strategy, providing a single source of truth for the patient while delivering actionable insights to their care providers.

The Business of Better Outcomes: Value-Based Care

This acquisition is about more than just technological synergy; it’s a calculated move within the healthcare industry's broader shift toward value-based care (VBC). In a VBC model, providers are compensated based on patient health outcomes rather than the volume of services delivered. This creates a powerful financial incentive to keep patients healthy and prevent costly complications.

Maternal health is a prime area for VBC innovation. The combined MediKarma-Nanell platform is positioned to deliver tangible value to payors and employers by enabling "earlier risk visibility" and reducing "fewer avoidable costs." By continuously monitoring at-risk pregnancies, the platform can trigger timely interventions, potentially reducing emergency room visits, lowering C-section rates, and shortening neonatal intensive care unit (NICU) stays—all major drivers of healthcare spending.

For employers, who are increasingly focused on the return on investment of their health benefits, the case is compelling. Comprehensive maternal health support has been linked to higher employee retention, improved productivity, and lower overall healthcare claims. By offering a sophisticated tool that supports employees through a pivotal life stage, companies can enhance their benefits package while simultaneously managing costs.

A Strategic Play for a Global Giant

For the seller, Niterra Co., Ltd., the deal represents a successful milestone in a much larger corporate transformation. Known for decades as NGK Spark Plug, a leader in automotive components, Niterra is actively diversifying its portfolio away from the internal combustion engine industry. The company has set ambitious goals to grow its non-automotive business, targeting areas like health, energy, and mobility under its "Niterra BX" long-term management plan.

Niterra Ventures Company, its corporate venture arm, is the engine of this change. Its mandate is to build or invest in "New Core Assets" that align with a vision of improving quality of life. Nanell was born from this internal innovation process, built from the ground up after researching the needs of expectant mothers.

Divesting Nanell to a strategic partner like MediKarma validates this model. It allows Niterra to successfully launch an innovative solution and then place it in an ecosystem where it can scale effectively, while Niterra retains a stake in its future success. The deal's structure, which includes equity-linked consideration and a revenue-share component, ensures Niterra will benefit as the technology grows within MediKarma's platform.

“We believe MediKarma’s platform is the perfect strategic home for Nanell’s next chapter," commented Dirk Schapeler, President of Niterra Ventures Company. "It connects specialized pregnancy insights to a longitudinal profile that ultimately benefits both members and care teams. We are excited to support MediKarma’s growth as it scales this unified capability."

This strategic divestment allows Niterra to realize a return on its innovation while continuing to focus on its broader diversification strategy, which includes other investments in medical technology startups. The successful transition of Nanell serves as a powerful proof point for the company's ability to innovate beyond its legacy markets and contribute to solving pressing social issues through technology.